Cargando…

The hypocretins and the reward function: what have we learned so far?

A general consensus acknowledges that drug consumption (including alcohol, tobacco, and illicit drugs) constitutes the leading cause of preventable death worldwide. But the global burden of drug abuse extends the mortality statistics. Indeed, the comorbid long-term debilitating effects of the diseas...

Descripción completa

Detalles Bibliográficos
Autores principales: Boutrel, Benjamin, Steiner, Nadia, Halfon, Olivier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3680710/
https://www.ncbi.nlm.nih.gov/pubmed/23781178
http://dx.doi.org/10.3389/fnbeh.2013.00059
_version_ 1782273153079181312
author Boutrel, Benjamin
Steiner, Nadia
Halfon, Olivier
author_facet Boutrel, Benjamin
Steiner, Nadia
Halfon, Olivier
author_sort Boutrel, Benjamin
collection PubMed
description A general consensus acknowledges that drug consumption (including alcohol, tobacco, and illicit drugs) constitutes the leading cause of preventable death worldwide. But the global burden of drug abuse extends the mortality statistics. Indeed, the comorbid long-term debilitating effects of the disease also significantly deteriorate the quality of life of individuals suffering from addiction disorders. Despite the large body of evidence delineating the cellular and molecular adaptations induced by chronic drug consumption, the brain mechanisms responsible for drug craving and relapse remain insufficiently understood, and even the most recent developments in the field have not brought significant improvement in the management of drug dependence. Though, recent preclinical evidence suggests that disrupting the hypocretin (orexin) system may serve as an anticraving medication therapy. Here, we discuss how the hypocretins, which orchestrate normal wakefulness, metabolic health and the execution of goal-oriented behaviors, may be compromised and contribute to elicit compulsive drug seeking. We propose an overview on the most recent studies demonstrating an important role for the hypocretin neuropeptide system in the regulation of drug reward and the prevention of drug relapse, and we question the relevance of disrupting the hypocretin system to alleviate symptoms of drug addiction.
format Online
Article
Text
id pubmed-3680710
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-36807102013-06-18 The hypocretins and the reward function: what have we learned so far? Boutrel, Benjamin Steiner, Nadia Halfon, Olivier Front Behav Neurosci Neuroscience A general consensus acknowledges that drug consumption (including alcohol, tobacco, and illicit drugs) constitutes the leading cause of preventable death worldwide. But the global burden of drug abuse extends the mortality statistics. Indeed, the comorbid long-term debilitating effects of the disease also significantly deteriorate the quality of life of individuals suffering from addiction disorders. Despite the large body of evidence delineating the cellular and molecular adaptations induced by chronic drug consumption, the brain mechanisms responsible for drug craving and relapse remain insufficiently understood, and even the most recent developments in the field have not brought significant improvement in the management of drug dependence. Though, recent preclinical evidence suggests that disrupting the hypocretin (orexin) system may serve as an anticraving medication therapy. Here, we discuss how the hypocretins, which orchestrate normal wakefulness, metabolic health and the execution of goal-oriented behaviors, may be compromised and contribute to elicit compulsive drug seeking. We propose an overview on the most recent studies demonstrating an important role for the hypocretin neuropeptide system in the regulation of drug reward and the prevention of drug relapse, and we question the relevance of disrupting the hypocretin system to alleviate symptoms of drug addiction. Frontiers Media S.A. 2013-06-13 /pmc/articles/PMC3680710/ /pubmed/23781178 http://dx.doi.org/10.3389/fnbeh.2013.00059 Text en Copyright © 2013 Boutrel, Steiner and Halfon. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc.
spellingShingle Neuroscience
Boutrel, Benjamin
Steiner, Nadia
Halfon, Olivier
The hypocretins and the reward function: what have we learned so far?
title The hypocretins and the reward function: what have we learned so far?
title_full The hypocretins and the reward function: what have we learned so far?
title_fullStr The hypocretins and the reward function: what have we learned so far?
title_full_unstemmed The hypocretins and the reward function: what have we learned so far?
title_short The hypocretins and the reward function: what have we learned so far?
title_sort hypocretins and the reward function: what have we learned so far?
topic Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3680710/
https://www.ncbi.nlm.nih.gov/pubmed/23781178
http://dx.doi.org/10.3389/fnbeh.2013.00059
work_keys_str_mv AT boutrelbenjamin thehypocretinsandtherewardfunctionwhathavewelearnedsofar
AT steinernadia thehypocretinsandtherewardfunctionwhathavewelearnedsofar
AT halfonolivier thehypocretinsandtherewardfunctionwhathavewelearnedsofar
AT boutrelbenjamin hypocretinsandtherewardfunctionwhathavewelearnedsofar
AT steinernadia hypocretinsandtherewardfunctionwhathavewelearnedsofar
AT halfonolivier hypocretinsandtherewardfunctionwhathavewelearnedsofar